TITAN study
| Study type | Summary | Inclusion Criteria | Participation requirements | Status |
| Randomised placebo-controlled study | The TITAN study is investigating the effect of three drugs on the latent HIV reservoir and HIV immune responses. These are lefitolimod (a drug designed to boost the immune system) and two broadly neutralising antibodies (proteins that can disable virus). Lefitolimod is given via an injection in the skin on the abdomen. The neutralising antibodies are given via intravenous infusion. This study involves a closely monitored 24-week treatment interruption. There are strict criteria to restart HIV treatment to ensure participant safety. | · HIV+ · Adults 18-65 years · On HIV treatment for >18 months · plasma RNA < 50 copies/mL for > 15 months · CD4 >500 | Participants will have screening blood collected to check if their HIV is sensitive to (or disabled by) the neutralising antibodies. Eligible participants will receive either lefitolomod, the broadly neutralising antibodies or placebo, and will need to attend approximately 20 study visits over a 6-month period. During the treatment interruption, participants are monitored every 1-2 weeks. | Recruitment closed |
Study contact
Contact: Alfred Clinical Research Unit on 03 9076 6908 or clinresearch@alfred.org.au
.png)